BR112021004542A2 - inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos - Google Patents
inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos Download PDFInfo
- Publication number
- BR112021004542A2 BR112021004542A2 BR112021004542-2A BR112021004542A BR112021004542A2 BR 112021004542 A2 BR112021004542 A2 BR 112021004542A2 BR 112021004542 A BR112021004542 A BR 112021004542A BR 112021004542 A2 BR112021004542 A2 BR 112021004542A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- pai
- inhibitor
- administration
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731074P | 2018-09-13 | 2018-09-13 | |
| US62/731,074 | 2018-09-13 | ||
| PCT/US2019/050849 WO2020056160A1 (en) | 2018-09-13 | 2019-09-12 | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021004542A2 true BR112021004542A2 (pt) | 2021-06-08 |
Family
ID=68052024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021004542-2A BR112021004542A2 (pt) | 2018-09-13 | 2019-09-12 | inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220105068A1 (https=) |
| EP (1) | EP3849539A1 (https=) |
| JP (2) | JP2021535925A (https=) |
| KR (2) | KR20250163416A (https=) |
| CN (2) | CN113056268A (https=) |
| AU (1) | AU2019338459B2 (https=) |
| BR (1) | BR112021004542A2 (https=) |
| CA (1) | CA3112558A1 (https=) |
| IL (1) | IL281450A (https=) |
| MX (2) | MX2021002995A (https=) |
| SG (1) | SG11202102478SA (https=) |
| WO (1) | WO2020056160A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| CN113155987B (zh) * | 2020-12-28 | 2023-06-06 | 浙江工商大学 | 一种微针贴片及其制备方法、应用 |
| AU2024344613A1 (en) | 2023-09-18 | 2026-04-23 | Eirion Therapeutics, Inc. | Topical compositions and uses of pai-1 inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| AU2001229441A1 (en) * | 2000-01-14 | 2001-07-24 | Tanox, Inc. | Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| WO2003071267A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| AU2005274574B2 (en) * | 2004-08-18 | 2011-03-17 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
| KR102110379B1 (ko) | 2005-12-01 | 2020-05-14 | 유니버시티 오브 메사츄세츠 로웰 | 보툴리눔 나노에멀젼 |
| US8658391B2 (en) | 2006-04-27 | 2014-02-25 | Anterios, Inc. | Assessment of the effects of topical administration of chemodenervating pharmaceuticals |
| SG177184A1 (en) | 2006-12-01 | 2012-01-30 | Anterios Inc | Amphiphilic entity nanoparticles |
| EP2272822A4 (en) * | 2008-03-31 | 2012-01-18 | Renascience Co Ltd | PLASMINOG ACTIVATOR-1 HEMMER |
| KR101848095B1 (ko) | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| WO2010148572A1 (en) * | 2009-06-26 | 2010-12-29 | Asan Laboratories Co., Ltd. | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| US20120328701A1 (en) | 2011-01-24 | 2012-12-27 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| BR112013018918A2 (pt) | 2011-01-24 | 2016-10-04 | Anterios Inc | composições de nanopartículas |
| US9144671B2 (en) | 2011-12-21 | 2015-09-29 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
-
2019
- 2019-09-12 KR KR1020257037244A patent/KR20250163416A/ko active Pending
- 2019-09-12 AU AU2019338459A patent/AU2019338459B2/en active Active
- 2019-09-12 JP JP2021514401A patent/JP2021535925A/ja active Pending
- 2019-09-12 CN CN201980074633.8A patent/CN113056268A/zh active Pending
- 2019-09-12 KR KR1020217010851A patent/KR102884331B1/ko active Active
- 2019-09-12 WO PCT/US2019/050849 patent/WO2020056160A1/en not_active Ceased
- 2019-09-12 MX MX2021002995A patent/MX2021002995A/es unknown
- 2019-09-12 CA CA3112558A patent/CA3112558A1/en active Pending
- 2019-09-12 US US17/274,948 patent/US20220105068A1/en active Pending
- 2019-09-12 EP EP19773718.2A patent/EP3849539A1/en active Pending
- 2019-09-12 SG SG11202102478SA patent/SG11202102478SA/en unknown
- 2019-09-12 BR BR112021004542-2A patent/BR112021004542A2/pt unknown
- 2019-09-12 CN CN202511057022.6A patent/CN120983628A/zh active Pending
-
2021
- 2021-03-11 IL IL281450A patent/IL281450A/en unknown
- 2021-03-12 MX MX2025004193A patent/MX2025004193A/es unknown
-
2024
- 2024-09-12 JP JP2024158484A patent/JP2025011085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021002995A (es) | 2021-07-15 |
| US20220105068A1 (en) | 2022-04-07 |
| KR102884331B1 (ko) | 2025-11-13 |
| MX2025004193A (es) | 2025-05-02 |
| CN113056268A (zh) | 2021-06-29 |
| EP3849539A1 (en) | 2021-07-21 |
| KR20250163416A (ko) | 2025-11-20 |
| IL281450A (en) | 2021-04-29 |
| WO2020056160A1 (en) | 2020-03-19 |
| AU2019338459A1 (en) | 2021-04-08 |
| JP2021535925A (ja) | 2021-12-23 |
| CA3112558A1 (en) | 2020-03-19 |
| AU2019338459B2 (en) | 2025-07-10 |
| CN120983628A (zh) | 2025-11-21 |
| SG11202102478SA (en) | 2021-04-29 |
| JP2025011085A (ja) | 2025-01-23 |
| KR20210057141A (ko) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2618907T3 (es) | Composiciones farmacéuticas en crema que comprenden oximetazolina | |
| JP5570992B2 (ja) | 皮膚病又は皮膚病変の治療方法及び組成物 | |
| JP2014503587A (ja) | 界面活性剤組成物 | |
| JP3331414B2 (ja) | 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途 | |
| JP2025011085A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）およびその使用 | |
| US8952060B2 (en) | Composition for preventing hair loss or for stimulating hair growth | |
| JP2025138639A (ja) | プラスミノーゲンアクチベーターインヒビター１（ｐｌａｓｍｉｎｏｇｅｎ ａｃｔｉｖａｔｏｒ ｉｎｈｉｂｉｔｏｒ １）（ＰＡＩ－１）阻害剤（ｉｎｈｉｂｉｔｏｒ）の使用 | |
| CN105101964A (zh) | 选择性δ-阿片受体拮抗剂和特异性感觉器配体的用途 | |
| JP6656890B2 (ja) | フィラグリン産生促進剤 | |
| HK40055571A (en) | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor | |
| JP2022044038A (ja) | ドネペジル含有経皮吸収液剤およびその製造方法 | |
| AU2024344613A1 (en) | Topical compositions and uses of pai-1 inhibitors | |
| HK40055572A (en) | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors | |
| KR20200034769A (ko) | 체지방 감소를 위한 프로스타시클린 수용체 작용제 | |
| BR112021003746A2 (pt) | sistema de distribuição transdermal de fármacos | |
| BR112021003746B1 (pt) | Formulação para distribuição transdérmica de um ingrediente ativo a um mamífero, e kit | |
| CN105555264A (zh) | 三氟乙酸作为治疗过度角化皮肤损伤的角质层分离剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023017087-3 PROTOCOLO 870230075123 EM 24/08/2023 15:25. |